Psoriasis and metabolic disease: epidemiology and pathophysiology - Test2 - elhamkhani - TriplyDB

Psoriasis and metabolic disease: epidemiology and pathophysiology

Psoriasis and metabolic disease: epidemiology and pathophysiology

http://www.wikidata.org/entity/Q37102789

about

Immunology of psoriasis Putting together the psoriasis puzzle: an update on developing targeted therapies Skin-targeted inhibition of PPAR β/δ by selective antagonists to treat PPAR β/δ-mediated psoriasis-like skin disease in vivo Pharmacological undertreatment of coronary risk factors in patients with psoriasis: observational study of the Danish nationwide registries Activation of PPARbeta/delta causes a psoriasis-like skin disease in vivo.Exploring the link between cadmium and psoriasis in a nationally representative sample The risk of stroke in patients with psoriasis Vitamin D and its role in psoriasis: An overview of the dermatologist and nutritionist.Diet and weight loss as a treatment for psoriasis.Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database.Anti-psoriatic activity of Givotia rottleriformis in rats Spectral imaging reveals microvessel physiology and function from anastomoses to thromboses.The role of TNF inhibitors in psoriasis therapy: new implications for associated comorbidities.The brain-skin connection: role of psychosocial factors and neuropeptides in psoriasis.Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K.Association of psoriasis with stroke and myocardial infarction: meta-analysis of cohort studies.Prognosis after percutaneous coronary intervention in patients with psoriasis: a cohort study using Danish nationwide registries.Resolved psoriasis lesions retain expression of a subset of disease-related genes Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003-2006.LC-MS metabolomics of psoriasis patients reveals disease severity-dependent increases in circulating amino acids that are ameliorated by anti-TNFα treatment.Alkyloxy carbonyl modified hexapeptides as a high affinity compounds for Wnt5A protein in the treatment of psoriasis.Systemic role for vitamin d in the treatment of psoriasis and metabolic syndrome Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT): a pilot study The association of psoriasis and elevated blood lipids in overweight and obese children.Psoriasis and dyslipidemia.Cardiovascular comorbiditiy in psoriasis Psoriasis and metabolic syndrome.Bone mineral density and body composition in postmenopausal women with psoriasis and psoriatic arthritis.Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom.Analysis of cardiovascular risk factors and metabolic syndrome in korean patients with psoriasis.Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2015 MauiDerm Meeting Magnetic Resonance Elastography for Liver Fibrosis in Methotrexate Treatment.Prevalence of cardiovascular disease risk factors, and metabolic syndrome and its components in patients with psoriasis aged 30 to 49 years Evaluating practice patterns for managing moderate to severe plaque psoriasis: role of the family physician.Psoriasis and cardiovascular risk: strength in numbers, part II.The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004.Metabolic syndrome in patients with psoriatic disease.The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses.Visualization of atherosclerosis as detected by coronary artery calcium and carotid intima-media thickness reveals significant atherosclerosis in a cross-sectional study of psoriasis patients in a tertiary care center.Cardiometabolic risk in psoriasis: differential effects of biologic agents.

P2860

Q26995800-300A7D27-60EB-4A2B-B101-D487CF718D5E Q27026785-AB1C9F77-2327-4B47-973D-38587E651A7C Q28483670-62342CB2-D3F6-4515-9C65-758668F784C4 Q28730205-357D218F-9004-47AE-93DD-55EABB3A160D Q33543078-DBDE36A9-17F1-49D8-861A-7B446AFDC224 Q33687498-05BE1DBB-3D63-4B32-8512-82AE7D01C675 Q33831094-439C47A6-BDA1-468F-8D0D-5AC82FACA4EF Q33841808-661C3393-28FA-4EE5-B86A-8414118EEECD Q33940511-ED2F95C5-D6C0-4188-8B18-D4CB59AC1381 Q33951592-895E7D69-48D1-4F73-9A4F-79E13A1A88A1 Q33987266-E4140739-4993-4425-979C-B2A19F6AEB65 Q34049847-305439A3-08AC-44BD-AEC6-FDCC255C6BBB Q34076431-B7FF9902-25B6-4B70-B249-DF1255775F46 Q34080687-7E63B9A0-6D79-4492-B08C-940AD28AC8F8 Q34253312-E4F9B3F0-AF0D-44FC-862A-25A996382E67 Q34381490-44B9A26D-AB4E-4D43-B76C-9406676E2BE3 Q34420240-E166E819-1690-4D12-B0B5-1FAD209587D4 Q34490905-E39B9F0F-759A-48EF-8E40-C4D767FC4845 Q34785993-737F7EE0-33CD-4C30-9795-93DBCC368AC5 Q34855603-6432B784-0158-4CBC-AF1E-E7132E913719 Q35033149-39159171-3049-4E06-9BAB-CAE744F386D9 Q35089915-5E73D730-1B83-4BFE-8A24-FE6AD9C71250 Q35171276-E5537A6D-0108-4A03-A86C-0E1BFA240D76 Q35199755-E8581CA6-51D9-4642-8089-BDB599F35DFB Q35263254-2B096576-48C4-42A6-9839-612C5E34DDBC Q35564655-96874C46-1E16-42AD-A149-0CC4939A9E18 Q35601338-75E9C639-1931-4903-BF78-8FD94DE48BD5 Q35620308-34E1EAE6-CB9C-4793-9C51-38B2FDD71B57 Q35753936-0FBAAD7C-314C-4B4B-9126-B17CD79B86AB Q35770123-9AF4526E-8E5C-47C0-93A0-C1001EA34910 Q35822379-CE1CD63C-C513-49B5-A318-538AECB9B100 Q36036715-7F71D23C-2C84-4529-890E-753E39C8B177 Q36048427-75CA0738-CD15-4503-95C4-33EE0C5AFD19 Q36091617-ED0AAB34-7D08-4820-BC2C-2DC303737E47 Q36185077-738C5333-7270-4BBE-B019-505C11DA71C6 Q36602668-4A334330-5539-422B-9094-DD4B2CABFEE2 Q36897095-D77BF58F-493F-4287-94C0-41D90E5D670A Q37040371-1DF93C7B-D0B1-403B-922A-7F3F5905116F Q37118037-2CF74EF9-3192-427C-813D-9A90EFBC5BDF Q37145684-3544BA5F-2582-4615-95F1-62B491518A8A

P2860

Psoriasis and metabolic disease: epidemiology and pathophysiology

http://www.wikidata.org/entity/Q37102789

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on July 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Psoriasis and metabolic disease: epidemiology and pathophysiology

@en

Psoriasis and metabolic disease: epidemiology and pathophysiology.

@nl

type

label

Psoriasis and metabolic disease: epidemiology and pathophysiology

@en

Psoriasis and metabolic disease: epidemiology and pathophysiology.

@nl

prefLabel

Psoriasis and metabolic disease: epidemiology and pathophysiology

@en

Psoriasis and metabolic disease: epidemiology and pathophysiology.

@nl

P1433

Q37102789-20B37840-E897-4555-9FE3-9F2037067551

P1476

Q37102789-9BC28600-E82E-4822-8512-DF352875E90F

P2093

Q37102789-A5AF7F38-50BF-4856-BBCE-AF55A2C2A8B8

P2860

Q37102789-0FDA75E7-BD5E-479B-80D3-9C94F000DC74

Q37102789-1BB3C97A-A0B2-476E-9DAE-31D1C6C19CA7

Q37102789-21EF1738-F16A-4A87-9E69-7199A2845633

Q37102789-2B9E8D19-CA00-40E9-BC1F-3F4D73824CAC

Q37102789-3B78B237-7330-4BAD-8356-2A4068EE3AEA

Q37102789-49B0DC1B-BDE1-4D00-9EFD-17D3A518B830

Q37102789-56727ADA-AFAD-4FD3-AC2E-06524AEC41FF

Q37102789-63988D8B-94AE-4D30-B407-AADB74F5E012

Q37102789-63E51E9B-4984-45B6-92BE-75DACA83B707

Q37102789-65805277-AF89-49AF-A2CE-C9BCBDB45151

P304

Q37102789-6A20F013-86B0-4430-A484-74339727B9E6

P31

Q37102789-0D5FD9F5-4932-4F1F-8B93-68674B638E16

P356

Q37102789-A315D628-6E88-4B2B-A11C-5958A424CAF6

P433

Q37102789-80CC205A-EDAB-44E1-93B1-18B862862DAF

P478

Q37102789-3E9A29D2-CEE0-4A55-9BAB-D6C9DED80D74

P50

Q37102789-EBA66121-6E0B-4294-8B60-6ECD3AD3BBF1

P577

Q37102789-9F9DEDB4-6B33-4684-9BF7-2482C96D4C90

P5875

Q37102789-95DAF785-2ADE-4675-8B08-C816FF6EC291

P698

Q37102789-E7879922-49DB-42BA-B76B-F08180D062AA

P921

Q37102789-131E15F0-6DF5-4019-B1EE-08D85CCBFDE8

Q37102789-3ACB5CE9-1F75-436C-96F5-729221B386AD

P932

Q37102789-D0F3ED06-FA52-49FC-9478-EE2841D0B3A1

P356

BOR.0B013E3283031C99

P1433

Current Opinion in Rheumatology

P1476

Psoriasis and metabolic disease: epidemiology and pathophysiology

@en

P2093

Rahat S Azfar

http://www.w3.org/2001/XMLSchema#string

P2860

Endothelial progenitor cells in cardiovascular disorders

A variant in CDKAL1 influences insulin response and risk of type 2 diabetes

Early increase in levels of soluble inter-cellular adhesion molecule-1 (sICAM-1); potential risk factor for the acute coronary syndromes.

IL-20: biological functions and clinical implications.

Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study.

Insulin-like growth factor-II regulates the 12-lipoxygenase gene expression and promotes cell proliferation in human keratinocytes via the extracellular regulatory kinase and phosphatidylinositol 3-kinase pathways.

Angiogenesis modulates adipogenesis and obesity.

Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity

Insulin-like growth factor II and its receptors in atherosclerosis and in conditions predisposing to atherosclerosis.

Accumulation of oxidized low-density lipoprotein in psoriatic skin and changes of plasma lipid levels in psoriatic patients.

P304

416-422

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/BOR.0B013E3283031C99

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51401640

http://www.w3.org/2001/XMLSchema#string

P698

18525354

http://www.w3.org/2001/XMLSchema#string

P921

pathophysiology

P932

3746494

http://www.w3.org/2001/XMLSchema#string